Last reviewed · How we verify
ZD1839
ZD1839 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling to inhibit cancer cell proliferation.
ZD1839 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling to inhibit cancer cell proliferation. Used for Non-small cell lung cancer (NSCLC), Head and neck cancer.
At a glance
| Generic name | ZD1839 |
|---|---|
| Also known as | gefitinib, Iressa ®, IRESSA, Iressa, Gefitinib, IRESSA® |
| Sponsor | University of Chicago |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ZD1839 selectively inhibits the intracellular tyrosine kinase domain of EGFR, preventing autophosphorylation and downstream signaling through the MAPK and PI3K/AKT pathways. This leads to cell cycle arrest and apoptosis in EGFR-dependent tumors. It is an orally bioavailable small molecule designed to target EGFR-driven cancers.
Approved indications
- Non-small cell lung cancer (NSCLC)
- Head and neck cancer
Common side effects
- Rash/dermatitis
- Diarrhea
- Nausea
- Vomiting
- Anorexia
- Fatigue
Key clinical trials
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (PHASE2)
- Therapy for Advanced NSCLC With EGFR 19delins Mutation (EARLY_PHASE1)
- A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone (PHASE2)
- Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (PHASE3)
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (PHASE1)
- A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZD1839 CI brief — competitive landscape report
- ZD1839 updates RSS · CI watch RSS
- University of Chicago portfolio CI